亚太地区急诊症候群检测市场：分析与预测（2023-2033）

2023年亚太地区急性护理综合症检测市场规模为7.8亿美元，2023年至2033年复合年增长率为10.97%，预计2033年将达22亿美元。

由于全球暖化加剧，感染疾病率增加、流行病爆发以及在各地区发现新的传染病，因此对早期检测感染疾病的需求不断增加，从而推动了市场的成长。

亚太地区（亚太地区）急性护理症候群检测市场正在经历强劲成长，并在该地区的医疗保健形势中占据重要地位。症状检测在快速诊断和管理急性疾病以及及时应对疫情和紧急情况方面发挥着至关重要的作用。这一市场扩张是由感染疾病流行率上升、人们对早期诊断重要性的认识不断提高以及诊断技术的进步等因素所推动的。

近年来，亚太地区在医疗保健基础设施方面进行了大量投资，并引入了创新的诊断解决方案。这些投资加强了急性护理症候群检测市场，使紧急护理和严重护理环境中的诊断更快、更准确。此外，持续的 COVID-19 大流行凸显了症状检测在公共卫生应对中的关键作用，进一步刺激了全部区域对此类检测解决方案的需求。

本报告探讨了亚太地区急性护理综合症检测市场，提供了市场概述、最终用户、国家/地区的趋势以及参与市场的公司概况。

目录

执行摘要

第一章 市场

• 市场范围
• 调查方法

第二章 市场概况

• 概述
• 急性护理症候群检测的工作流程分析
• 市场足迹和成长潜力
• 未来性

第三章业界考察

• 相关利益者观点（N=20）
• 急诊护理症候群检测市场的法律和法律规范
• 产品基准评效

第四章市场动态

• 概述
• 影响分析
• 市场驱动力
• 市场挑战
• 市场机会

第五章 2022-2033年急性医学症候群检测市场（分地区）

• 概述
• 亚太地区
  • 亚太地区急性护理症候群检测市场，依最终用户划分
  • 亚太地区急性护理症候群检测市场（依国家）

第六章 公司简介

• Acute Care Syndromic Testing Ecosystem Active Players
• Seegene Inc.
• SpeeDx

“The Asia-Pacific Acute Care Syndromic Testing Market Expected to Reach $2.20 Billion by 2033.”

Introduction to Asia-Pacific Acute Care Syndromic Testing Market

The Asia-Pacific acute care syndromic testing market was valued at $0.78 billion in 2023 and is expected to reach $2.20 billion by 2033, growing at a CAGR of 10.97% between 2023 and 2033. The growth of the market can be attributed to the rising need for early detection of infectious diseases, driven by the growing incidence of such diseases, the occurrence of pandemics, and the identification of new infectious diseases in various regions, exacerbated by global warming.

Market Introduction

The Asia-Pacific (APAC) acute care syndromic testing market is experiencing robust growth and increasing prominence in the region's healthcare landscape. Syndromic testing plays a pivotal role in rapidly diagnosing and managing acute illnesses, offering a timely response to outbreaks and emergencies. This market's expansion is driven by factors such as the rising incidence of infectious diseases, growing awareness of the importance of early diagnosis, and advancements in diagnostic technologies.

In recent years, APAC has witnessed significant investments in healthcare infrastructure and the adoption of innovative diagnostic solutions. These investments have bolstered the acute care syndromic testing market, enabling quicker and more accurate diagnoses in emergency and critical care settings. Furthermore, the ongoing COVID-19 pandemic has underscored the critical role of syndromic testing in public health response, further fueling the demand for such testing solutions across the APAC region.

Market Segmentation:

Segmentation 1: by End User

• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users

Segmentation 2: by Country

• Japan
• India
• China
• South Korea
• Australia
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Synergistic activities, product launches, and approvals accounted for the maximum number of key developments.

Competitive Strategy: The APAC acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the APAC acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

Table of Contents

Executive Summary

1. Markets

• 1.1. Market Scope
  • 1.1.1. Key Questions Answered in the Report
• 1.2. Research Methodology
  • 1.2.1. Acute Care Syndromic Testing Market: Research Methodology
  • 1.2.2. Data Sources
    • 1.2.2.1. Primary Data Sources
    • 1.2.2.2. Secondary Data Sources
  • 1.2.3. Market Estimation Model
  • 1.2.4. Criteria for Company Profiling

2. Market Overview

• 2.1. Overview
• 2.2. Acute Care Syndromic Testing Workflow Analysis
• 2.3. Market Footprint and Growth Potential
• 2.4. Future Potential

3. Industry Insight

• 3.1. Stakeholder's Perspective (N=20)
  • 3.1.1. Physician's Perception
  • 3.1.2. Payor's Perception
  • 3.1.3. Investor's Perception
• 3.2. Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
  • 3.2.1. Regulatory Framework in Asia-Pacific
    • 3.2.1.1. Japan
    • 3.2.1.2. China
    • 3.2.1.3. India
    • 3.2.1.4. South Korea
    • 3.2.1.5. Australia
• 3.3. Product Benchmarking

4. Market Dynamics

• 4.1. Overview
• 4.2. Impact Analysis
• 4.3. Market Drivers
  • 4.3.1. Faster Results Acquired with Syndromic Tests
  • 4.3.2. Increasing Incidence of Infectious Diseases
  • 4.3.3. Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
  • 4.3.4. Reduced Severe Adverse Effects from Pathogens
• 4.4. Market Challenges
  • 4.4.1. Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
  • 4.4.2. Lack of High-Complexity Testing Centres
• 4.5. Market Opportunities
  • 4.5.1. Quick Access to Treatment and Reduced Use of Antibiotics
  • 4.5.2. High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5. Acute Care Syndromic Testing Market (By Region), 2022-2033

• 5.1. Overview
• 5.2. Asia-Pacific
  • 5.2.1. Asia-Pacific Acute Care Syndromic Testing Market, By End User
  • 5.2.2. Asia-Pacific Acute Care Syndromic Testing Market, By Country
    • 5.2.2.1. China
    • 5.2.2.2. Japan
    • 5.2.2.3. India
    • 5.2.2.4. Australia
    • 5.2.2.5. South Korea
    • 5.2.2.6. Rest-of-Asia-Pacific

6. Company Profiles

• 6.1. Overview
• 6.2. Acute Care Syndromic Testing Ecosystem Active Players
• 6.3. Seegene Inc.
  • 6.3.1. Company Overview
  • 6.3.2. Role of Seegene, Inc. in the Acute Care Syndromic Testing Market
  • 6.3.3. Financials
  • 6.3.4. Recent Developments
    • 6.3.4.1. Corporate Strategies
    • 6.3.4.2. Business Strategies
  • 6.3.5. Analyst Perspective
• 6.4. SpeeDx
  • 6.4.1. Company Overview
  • 6.4.2. Role of SpeeDX in the Acute Care Syndromic Testing Market
  • 6.4.3. Analyst Perspective

List of Figures

• Figure 1: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
• Figure 2: History of Known Pandemics
• Figure 3: Share of Acute Care Syndromic Testing Market (by Region), 2022
• Figure 4: Share of Key Developments and Strategies, January 2020-June 2023
• Figure 5: Acute Care Syndromic Testing Market (by Company), Share (%), 2022
• Figure 6: Acute Care Syndromic Testing Market: Research Methodology
• Figure 7: Primary Research Methodology
• Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 9: Top-Down Approach (Segment-Wise Analysis)
• Figure 10: Acute Care Syndromic Testing Workflow
• Figure 11: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
• Figure 12: Physician's Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
• Figure 13: Acute Care Syndromic Testing Market Dynamics
• Figure 14: Traditional Testing vs. Syndromic Testing
• Figure 15: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
• Figure 16: Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
• Figure 17: Incidence of Common Infectious Diseases in China, 2020
• Figure 18: History of Known Pandemics
• Figure 19: Examples of Cost Reductions
• Figure 20: Time of Diagnosis vs. Disease Effect
• Figure 21: Syndromic Panels Reimbursement Scenario in the U.S.
• Figure 22: Syndromic Panels Reimbursement Scenario in Mexico
• Figure 23: Reduction in Antibiotics Use with Syndromic Testing
• Figure 24: Increasing Synergistic Activities of the Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
• Figure 25: Key Mergers and Acquisitions in the Acute Care Syndromic Testing Market
• Figure 26: Acute Care Syndromic Testing Market Snapshot (by Region)
• Figure 27: Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
• Figure 28: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
• Figure 29: Asia-Pacific Acute Care Syndromic Testing Market (by End User), $Billion, 2022-2033
• Figure 30: Asia-Pacific Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
• Figure 31: Reported Cases of Top 5 Infectious Diseases, China, 2020
• Figure 32: China Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 33: Japan Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 34: India Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 35: Incidence of the Most Common Infectious Diseases in Australia, 2021
• Figure 36: Australia Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 37: South Korea Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 38: Rest-of-Asia-Pacific Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 39: Acute Care Syndromic Testing Market, Total Number of Companies Profiled
• Figure 40: Seegene, Inc.: Product Portfolio
• Figure 41: Seegene, Inc.: Overall Financials, $Million, 2020-2022
• Figure 42: Seegene, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 43: Seegene, Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 44: Seegene, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 45: SpeeDX: Product Portfolio

List of Tables

• Table 1: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
• Table 2: Acute Care Syndromic Testing Market: Impact Analysis
• Table 3: Key Questions Answered in the Report
• Table 4: Product Benchmarking of Acute Care Syndromic Testing Panels
• Table 5: Likert Scale
• Table 6: Impact Analysis of Market Drivers
• Table 7: Impact Analysis of Market Challenges
• Table 8: Popular Assays and Their Turnaround Times
• Table 9: Acute Care Syndromic Testing Ecosystem Active Players